Oragenics Inc. (OGEN) has completed a crucial study demonstrating the effectiveness of its new concussion drug, ONP-002, in reaching the brain via nasal delivery. This promising result puts the company closer to conducting human trials, offering potential hope for a much-needed treatment for concussions.